Holen Sie sich die Stockscreener-App
13.39
9.95%
-1.48
Handel nachbörslich:
13.65
0.26
+1.94%
Schlusskurs vom Vortag:
$14.87
Offen:
$14.87
24-Stunden-Volumen:
7.09M
Relative Volume:
1.10
Marktkapitalisierung:
$4.68B
Einnahmen:
Nettoeinkommen (Verlust:
$-277.02M
KGV:
-14.35
EPS:
-0.9328
Netto-Cashflow:
$-91.36M
1W Leistung:
-16.47%
1M Leistung:
-12.83%
6M Leistung:
-26.55%
1J Leistung:
+429.25%
1-Tages-Spanne:
$13.27
$14.87
1-Wochen-Bereich:
$13.27
$16.01
52-Wochen-Spanne:
$2.105
$24.28
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
13.39 | 4.68B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - GlobeNewswire Inc.
Erasca, Inc. (NASDAQ: ERAS) foundation plans another ERAS stock sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect - ACCESS Newswire
Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2026. - marketscreener.com
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - manilatimes.net
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca stock holds gains as FDA Fast Track boosts cancer pipeline - ad-hoc-news.de
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Yahoo Finance
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewswire
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors? - simplywall.st
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Stockholders to Connect - ACCESS Newswire
Erasca receives FDA fast track status for pancreatic cancer drug - investing.com
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Eastern Progress
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - Eastern Progress
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com India
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com UK
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Erasca (NASDAQ: ERAS) foundation to sell 8,333 shares - Stock Titan
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - simplywall.st
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - simplywall.st
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - webull.com
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Erasca Inc-Aktie (ERAS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Erasca Foundation | Foundation |
Sep 15 '26 |
Proposed Sale |
15.97 |
8,333 |
133,094 |
0 |
| Erasca Foundation | Foundation |
Aug 17 '26 |
Proposed Sale |
18.29 |
8,333 |
152,419 |
0 |
| Erasca Foundation | Foundation |
Jul 21 '26 |
Proposed Sale |
18.92 |
8,333 |
157,638 |
0 |
| Erasca Foundation | Foundation |
Jun 15 '26 |
Proposed Sale |
14.10 |
8,333 |
117,477 |
0 |
| Erasca Foundation | Foundation |
May 15 '26 |
Proposed Sale |
10.14 |
8,333 |
84,528 |
0 |
| Erasca Foundation | Foundation |
Apr 15 '26 |
Proposed Sale |
18.10 |
8,333 |
150,843 |
0 |
| Garner Ebun | Chief Legal Officer |
Apr 01 '26 |
Sale |
16.40 |
80,000 |
1,312,000 |
25,076 |
| Ebun Garner | Officer |
Apr 01 '26 |
Proposed Sale |
16.40 |
80,000 |
1,312,355 |
0 |
| Garner Ebun | Chief Legal Officer |
Apr 01 '26 |
Option Exercise |
1.70 |
80,000 |
136,000 |
105,076 |
| Erasca Foundation | Foundation |
Mar 16 '26 |
Proposed Sale |
14.02 |
8,333 |
116,855 |
0 |
6.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):